InvestorsHub Logo
Followers 44
Posts 2387
Boards Moderated 0
Alias Born 08/09/2016

Re: amarinbullfromchicago post# 146900

Tuesday, 10/02/2018 12:48:57 PM

Tuesday, October 02, 2018 12:48:57 PM

Post# of 427087
Dan - I think they are both very important, and will be complementary. The journal article will be the most convincing because it is rigorously peer-reviewed (I agree NEJM is likely and the company's timeline is before end of 2018). However, the conference exposure will be the first place where details are provided, and should generate some good publicity if detailed results are as strong as expected.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News